The use of antiretroviral therapy has significantly reduced the number of deaths due to HIV/AIDS. However, no current therapy can suppress the virus completely, and as the HIV-infected population continues to live longer new complications are emerging from the persistence of the virus and use of antiretroviral therapy. This review summarizes the clinical evidence linking HIV-associated osteoporosis to direct infection and antiretroviral therapy (ART) use. The purported molecular mechanisms involved in bone loss are also reviewed. Additionally, recommendations regarding the pharmacologic management of HIV/ART-related osteoporosis are given.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalCurrent Osteoporosis Reports
Issue number4
StatePublished - Dec 2010


  • AIDS
  • BMD
  • Bone loss
  • HIV
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Nucleoside reverse transcriptase inhibitors (NRTIs)
  • Protease inhibitors


Dive into the research topics of 'HIV and bone loss'. Together they form a unique fingerprint.

Cite this